二重特異性抗体
二重特異性モノクローナル抗体
(二重特異性抗体 から転送)
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2022/07/02 15:52 UTC 版)
二重特異性モノクローナル抗体(Bispecific monoclonal antibody、BsMab)は、2種類の異なる抗原に同時に結合する人工的なタンパク質である。天然の抗体は、通常、1つの抗原のみを標的とする。BsMabは、いくつかの構造形式で製造することができ、現在、がん免疫療法やドラッグデリバリーへの応用が検討されている[1]。
- ^ a b c d e Fan, Gaowei; Wang, Zujian; Hao, Mingju; Li, Jinming (2015-12-21). “Bispecific antibodies and their applications”. Journal of Hematology & Oncology 8: 130. doi:10.1186/s13045-015-0227-0. ISSN 1756-8722. PMC 4687327. PMID 26692321 .
- ^ a b Liu, Hongyan; Saxena, Abhishek; Sidhu, Sachdev S.; Wu, Donghui (2017-01-01). “Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds”. Frontiers in Immunology 8: 38. doi:10.3389/fimmu.2017.00038. PMC 5266686. PMID 28184223 .
- ^ a b Mueller, D; Kontermann, RE (2010). “Bispecific antibodies for cancer immunotherapy”. BioDrugs 24 (2): 89–98. doi:10.2165/11530960-000000000-00000. PMID 20199124.
- ^ a b Chames, P; Baty, D (2009). “Bispecific antibodies for cancer therapy: The light at the end of the tunnel”. mAbs 1 (6): 539–547. doi:10.4161/mabs.1.6.10015. PMC 2791310. PMID 20073127 .
- ^ a b Lindhofer, H; Mocikat, R; Steipe, B; Thierfelder, S (1 July 1995). “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies”. Journal of Immunology 155 (1): 219–25. PMID 7602098 .
- ^ a b Yang, Fa; Wen, Weihong; Qin, Weijun (2016-12-28). “Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies” (英語). International Journal of Molecular Sciences 18 (1): 48. doi:10.3390/ijms18010048. PMC 5297683. PMID 28036020 .
- ^ a b Baeuerle, PA; Reinhardt, C (2009). “Bispecific T-cell engaging antibodies for cancer therapy”. Cancer Res 69 (12): 4941–4944. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221 .
- ^ Wozniak-Knopp, G.; Bartl, S.; Bauer, A.; Mostageer, M.; Woisetschlager, M.; Antes, B.; Ettl, K.; Kainer, M. et al. (2010-04-01). “Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties” (英語). Protein Engineering Design and Selection 23 (4): 289–297. doi:10.1093/protein/gzq005. ISSN 1741-0126. PMID 20150180.
- ^ a b Wec, Anna Z.; Nyakatura, Elisabeth K.; Herbert, Andrew S.; Howell, Katie A.; Holtsberg, Frederick W.; Bakken, Russell R.; Mittler, Eva; Christin, John R. et al. (2016-10-21). “A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses” (英語). Science 354 (6310): 350–354. Bibcode: 2016Sci...354..350W. doi:10.1126/science.aag3267. ISSN 0036-8075. PMC 5647781. PMID 27608667 .
- ^ a b Bargou, R; Leo, E; Zugmaier, G; Klinger, M; Goebeler, M; Knop, S; Noppeney, R; Viardot, A et al. (2008). “Tumor regression in cancer patients by very low doses of a T cell-engaging antibody”. Science 321 (5891): 974–977. Bibcode: 2008Sci...321..974B. doi:10.1126/science.1158545. PMID 18703743.
- ^ Weiner, LM; Holmes, M; Richeson, A; Godwin, A; Adams, GP; Hsieh-Ma, ST; Ring, DB; Alpaugh, RK (1993). “Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1”. Journal of Immunology 151 (5): 2877–86. PMID 8103070.
- ^ Varela, MA (2015). “Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypes”. BMC Genomics 16: 530. doi:10.1186/s12864-015-1727-6. PMC 4506634. PMID 26187740 .
- ^ Koustas, E; Sarantis, P (2020). “The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors”. Biomolecules 10 (5): 66-82. doi:10.3390/biom10050666. PMID 32344837.
- ^ Suurs, Frans V.; Lub-de Hooge, Marjolijn N.; de Vries, Elisabeth G. E.; de Groot, Derk Jan A. (2019-09-01). “A review of bispecific antibodies and antibody constructs in oncology and clinical challenges”. Pharmacology & Therapeutics 201: 103–119. doi:10.1016/j.pharmthera.2019.04.006. ISSN 0163-7258. PMID 31028837.
- ^ “Amivantamab Approved for EGFR Exon 20-Mutant NSCLC”. Cancer Discovery. (2021). doi:10.1158/2159-8290.CD-NB2021-0351. PMID 34083225.
- 1 二重特異性モノクローナル抗体とは
- 2 二重特異性モノクローナル抗体の概要
- 3 問題点
二重特異性抗体と同じ種類の言葉
- 二重特異性抗体のページへのリンク